Two well-received precision oncology IPOs closed out the week, joined by a successful ophthalmic specialty IPO and an immunotherapy debut that fell flat. P53 mutation...

Scientists long have puzzled over what goes wrong in people with cardiovascular disease. Now, they have created a cellular and molecular map of the healthy human heart,...

Using 3D tumor organoids, researchers have added to existing evidence that inhibition of kinesin spindle protein may represent a broadly relevant target for the treatment of the aggressive childhood tumor neuroblastoma.

HONG KONG – Chinese biotech companies, long in-licensors of innovative biopharma assets for the region, have started to reverse the flow by out-licensing domestically...